Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase 3 study A...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood Cancer J
मुख्य लेखकों: Dimopoulos, M A, Stewart, A K, Masszi, T, Špička, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D, Mihaylov, G G, Goranova-Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, A, San-Miguel, J, Ludwig, H, Ro, S, Aggarwal, S, Moreau, P, Palumbo, A
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group 2017
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436074/
https://ncbi.nlm.nih.gov/pubmed/28430175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.31
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन